Peptide therapy TikTok claims: what the science actually supports

What did @tren.baby2 actually say?

The creator described using melanotan II (MT2) for cosmetic tanning, reporting visible skin darkening after a few uses combined with tanning bed sessions. They said their moles were "getting darker," which has them considering switching to MT1. They also walked through the two most commonly reported side effects: nausea and facial flushing. Their personal experience? No nausea, but significant redness. "Look at my buddy Abe here, bro, this was like 20 minutes after we did it and bro is completely red." They recommend taking it at night so the flush isn't visible and you can sleep through any nausea. The video ends with a promo code for a vendor called "disguised research," which is a significant red flag we'll come back to.

To be clear about what MT2 is: melanotan II is a synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH). It was originally developed at the University of Arizona in the 1980s and 1990s as a potential sunless tanning agent and later explored for erectile dysfunction. It is not FDA-approved for any indication and is not legally available as a prescription drug in the United States.

Does the science back this up?

On the core tanning claim, yes, MT2 does cause skin darkening. That part is not contested. On safety, this is where the creator's breezy tone starts to feel irresponsible.

Melanotan II works by binding to melanocortin receptors (MC1R through MC5R), triggering melanogenesis even without UV exposure. Studies confirm it produces dose-dependent skin pigmentation. Eves et al. (2006, Peptides) documented increased eumelanin production in human subjects. So the "I'm looking darker" observation is real and physiologically explainable.

The flushing response the creator describes is also well-documented. It results from vasodilation triggered by MC1R and MC3R activation, and it typically peaks 30 to 90 minutes post-injection. This matches what the creator observed.

Nausea is also a real, common effect. A clinical review by Dorr et al. (1996, Journal of Laboratory and Clinical Medicine) found nausea occurred in a significant portion of subjects at higher doses. The creator's personal absence of nausea doesn't make it rare. It just means they may be dosing lower or have individual tolerance differences.

What did they get wrong (or right)?

They got the side effect profile roughly right. Flushing and nausea are the two most commonly reported acute effects, and the night-dosing tip to manage both is practical advice that actually aligns with what people in clinical settings have used to reduce symptom burden. Credit where it's due.

But the mole comment is where this gets genuinely concerning. "My moles, I feel like, are definitely getting darker." This is not a trivial cosmetic observation. Melanocortin receptor activation has been associated with changes in existing nevi (moles), and there are documented case reports of MT2 use preceding melanoma diagnosis. Langan et al. (2009, British Journal of Dermatology) reported cases of new pigmented lesions and changes in existing moles in MT2 users. The creator treats this as a minor inconvenience. It is not. Changing moles require dermatological evaluation, full stop.

The vendor plug for "disguised research" also warrants direct commentary. Unregulated peptide vendors selling injectable MT2 are not operating under pharmaceutical-grade manufacturing standards. Purity, sterility, and dosing accuracy are all unknowns. This is not a theoretical concern. It is a known contamination risk with gray-market injectables.

What should you actually know?

MT2 is not approved by the FDA. It is not available legally as a prescription drug in the US. It is sold through gray-market vendors as a "research chemical," which is the exact framing the creator uses when referencing "disguised research." That label does not make it safe or legal for human use.

The tanning effect is real, but so are the risks. Beyond flushing and nausea, the documented concerns include spontaneous erections (MC4R activation), changes in moles and nevi, elevated blood pressure, and the unresolved question of whether chronic melanocortin stimulation increases melanoma risk in susceptible individuals. Kadekaro et al. (2010, Pigment Cell and Melanoma Research) noted that alpha-MSH analogs can stimulate both normal and malignant melanocytes.

If you notice a mole changing color, size, or shape, the correct response is a dermatologist appointment, not switching peptide formulations. The creator's suggestion to "switch to MT1" as a fix for darkening moles is not medically sound reasoning.

• MT2 is not FDA-approved and cannot legally be marketed for human use in the US.
• Injectable products from unregulated vendors carry contamination and sterility risks that no promo code offsets.
• Changing moles are a clinical concern requiring evaluation, not a dosing problem to troubleshoot.